LSNE Contract Manufacturing has signed a manufacturing supply agreement with Selecta Biosciences. Selecta is a clinical-stage biopharmaceutical company focused on utilizing its Synthetic Vaccine Particle (SVP) platform to develop biologic therapies for rare and serious diseases that avoid the immune responses that compromise efficacy and lead to life-threatening complications. To support the development of these products, LSNE will provide drug substance manufacturing and fill/finish services.

“We are very excited to expand our existing relationship with Selecta,” said Matthew Halvorsen, president and chief executive officer, LSNE. “Our expertise in development and GMP manufacturing makes us a strong partner for their project. We look forward to working with their team on the late stage clinical programs, as well as future commercial manufacturing.”

Lloyd Johnston, chief operating officer, Selecta, said, “Selecta is focused on ensuring that it has the right processes and partners as we advance our lead program, SEL-212, through the clinic and toward the commercial stage. We are happy to have LSNE’s support as a clinical and commercial manufacturer of SVP-Rapamycin for SEL-212 and future product candidates.”